UNSPSC 51284908: Phenazopyridine/sulfamethoxazole

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM650. This VA Drug Class (AM650) classifies this compound as belonging to the group SULFONAMIDE/RELATED ANTIMICROBIALS.

UNSPSC 51284908 Phenazopyridine/sulfamethoxazole is a Commodity code, but the recent state and local opportunities tagged under it do not reflect its nominal pharmaceutical ingredient scope. Instead, the code shows activity across broader emergency medical supplies, naloxone and drug deactivation systems, pharmacy benefit management programs, and generic multi-source pharmaceuticals and over-the-counter products — a mismatch between the code's narrow chemical designation and what jurisdictions are actually procuring. State and local buyers issuing under this code include county health departments, city fire and rescue divisions, state pharmacy commissions and cooperative purchasing alliances, and state health and human services agencies. The procurement mix spans annual consumable supply agreements with quarterly delivery schedules, direct-to-manufacturer pharmacy prescription programs at the state level, and cooperative purchasing arrangements serving multiple government jurisdictions and employee health plans.

Recent activity concentrated in Florida, Texas, and Minnesota shows distinct procurement patterns. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building, due July 26, 2023. The City of Tampa's Purchasing Department released IFB 26P00145 in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, estimated at $700,000.00 and designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products, with proposals due March 26, 2026 and awards effective July 1, 2026, spanning Minnesota and Oregon participant agencies. The code shows little coherent recent activity tied to its nominal pharmaceutical ingredient scope.